In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Columbia Funds is in the process of consolidating governance into a unitary board by moving the seven funds in the Columbia Acorn Trust and Wanger Advisors ...
Guinness Atkinson Funds has added two new independent directors to bump the size of the board back up to six members following the year-end retirement of ...
Securities and Exchange Commission Chairman Gary Gensler’s fast and furious rulemaking era will soon be ending, and it is a good time to take stock of ...
Congress created business development companies in 1980 to support job growth and help emerging companies raise funds. As of 2023, there were 139 BDCs with $312 ...